Oncology Institute Adds Independent Director to Board

Oncology Institute ( (TOI) ) has issued an announcement.

The Oncology Institute, Inc., a leading U.S. value-based oncology group with over 100 clinics and affiliate locations across five states, delivers specialized, evidence-based cancer care and clinical trials to about 1.9 million patients. Operating in community settings with more than 180 clinicians, it aims to expand access to advanced oncology services while maintaining a focus on cost-effective, integrated care.

On February 23, 2026, The Oncology Institute appointed healthcare executive Kim Tzoumakas to its Board of Directors to fill a vacancy, confirming her independence under Nasdaq rules and eligibility for the company’s standard non-employee director pay and equity program. Her background in oncology, pharmacy services, operational turnarounds and integrated care models is expected to support TOI’s expansion of its care delivery and pharmacy businesses, potentially strengthening strategic execution and governance for stakeholders.

The most recent analyst rating on (TOI) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Oncology Institute stock, see the TOI Stock Forecast page.

Spark’s Take on TOI Stock

According to Spark, TipRanks’ AI Analyst, TOI is a Neutral.

The score is held down primarily by weak financial health (losses and negative equity) and bearish technicals (trading below key moving averages with negative MACD). These are partially offset by a more constructive earnings-call outlook with raised guidance and improving adjusted EBITDA trends, while valuation is difficult to assess due to negative earnings and no dividend support.

To see Spark’s full report on TOI stock, click here.

More about Oncology Institute

The Oncology Institute, Inc., listed on Nasdaq as TOI, is one of the largest value-based oncology groups in the United States, specializing in community-based, evidence-driven cancer care. Founded in 2007, it serves roughly 1.9 million patients through more than 180 employed and affiliate clinicians across over 100 clinics in five states, offering services such as clinical trials and transfusions.

The company focuses on delivering highly specialized, integrated oncology services traditionally associated with advanced academic centers, but in local community settings. Its model emphasizes value-based care, cost management, and expanded access to cutting-edge treatments as it continues to grow its clinical footprint and related pharmacy operations.

Average Trading Volume: 1,886,933

Technical Sentiment Signal: Sell

Current Market Cap: $255.8M

For detailed information about TOI stock, go to TipRanks’ Stock Analysis page.